[Pathogenesis of acute myocardial infarction. I. Complement activation in vivo and development of infarction].
We studied 53 patients within 12 hs from the onset of symptoms of acute myocardial infarction, and 25 healthy controls. We searched for complement split products in plasma treated with EDTA to avoid in vitro complement activation. Therefore the presence of proteolytic degradation products of C3 signals in vivo activation. Sixteen of the 53 cases (30%), had C3 splitting products in EDTA-plasma. In contrast only 2 (8%) controls showed C3 splitting products. In vivo complement activation correlated with the severity of the infarction.
D003167:Complement Activation; D003176:Complement C3 / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000276:immunology* / Q000473:pathology
D003176:Complement C3
Patogenia del infarto agudo del miocardio. (I.) Activación del complemento in vivo y evolución del infarto.